摘要
目的探讨阿托伐他汀对慢性肾脏病患者肾功能的影响。方法 72例慢性肾脏病患者随机分为两组。对照组32例,予以常规药物治疗;治疗组40例,加用阿托伐他汀20mg/d,随访观察12个月。入选时及观察期结束后检测AST、ALT、CK、Scr、BUN以及24h尿白蛋白定量。结果经12个月治疗后,两组患者治疗前后AST、ALT、CK差异均无统计学意义(P>0.05);对照组BUN、Scr、24h尿白蛋白较治疗前有所降低(P<0.05);治疗组BUN、Scr、24h尿白蛋白定量较治疗前显著降低(P<0.01);与对照组比较,治疗后治疗组血BUN、Scr均有所降低(P<0.05),24h尿白蛋白定量显著降低(P<0.01)。结论阿托伐他汀对慢性肾脏病患者具有一定治疗作用。
Objective To investigate the effects of atorvastatin on renal function in chronic kidney disease.Methods 72 CKD patients were divided randomly into experimental group（n=40） and control group（n=32）.Exprimeutal group received atorvastatin（20mg/d） on the basis of conventional treatment of control group.The levers of AST,ALT,CK,Scr,BUN and 24 hour urine protein quantitative were detected before and after 12 months treatment.Results There were no significant differences in the levels of AsT,AlT,and CK between the two groups before and after treatment（P 0.05）.After treatment the levels of Scr,BUN and 24 hour urine protein quantitative in control group were significantly lower than before treatment（P 0.05）.After treatment the levels of scr,bUN and 24 hour urine protein quantitative in experimenfal group were significantly lower than that of control and before treatment（P 0.05 and P 0.01）.conclusion Atorvastatin can efficiently improve renal function in chronic kidney disease.
出处
《医学研究与教育》
CAS
2012年第2期24-27,共4页
Medical Research and Education
关键词
阿托伐他汀
慢性肾脏病
尿蛋白定量
atorvastatin
chronic kidney disease
urine protein quantitative
